MRCKα (CDC42BPA) is a CDC42-binding serine/threonine kinase that promotes cytoskeletal reorganization downstream of CDC42
[1]. Mechanistically, MRCKα catalytic activity depends on N-terminal dimerization, trans-autophosphorylation, and relief of inhibitory kinase-coiled-coil interactions
[2]. This regulation connects MRCKα to actomyosin signaling, because CDC42-MRCK and Rho-ROCK pathways cooperate in myosin phosphorylation and cancer cell invasion
[3]. In epithelial models, caspase-cleaved MRCKα assembles an apical actin ring that drives apoptotic epithelial cell extrusion
[4]. Compared with related isoforms, MRCKα and MRCKβ are broadly expressed, whereas MRCKγ expression is restricted mainly to heart and skeletal muscle
[5]. Human MRCKα also shows multiple alternative splicing events that expand functional diversity
[6]. For experimental applications, BDP5290 reduces MLC phosphorylation, cell motility, and tumor-cell invasion, while BDP8900 and BDP9066 support studies of MRCK-dependent cancer viability, migration, and invasion
[7][8].- MRCKα studies fit cytoskeletal remodeling, epithelial extrusion, cancer invasion, and kinase-regulation projects
[1][3][4]. - Isoform controls should separate MRCKα/MRCKβ from muscle-enriched MRCKγ expression contexts
[5].